ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2023; 13(8):2471-2491. doi:10.7150/thno.82189 This issue Cite
Review
Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
1. Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
2. Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
3. Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
# These authors contributed equally.
Citation:
Fei W, Yan J, Wu X, Yang S, Zhang X, Wang R, Chen Y, Xu J, Zheng C. Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics. Theranostics 2023; 13(8):2471-2491. doi:10.7150/thno.82189. https://www.thno.org/v13p2471.htm
Other stylesAbstract
Cancer is generally considered a result of genetic mutations that cause epigenetic changes, leading to anomalous cellular behavior. Since 1970s, an increasing understanding of the plasma membrane and specifically the lipid alterations in tumor cells have provided novel insights for cancer therapy. Moreover, the advances in nanotechnology offer a potential opportunity to target the tumor plasma membrane while minimizing side effects on normal cells. To further develop membrane lipid perturbing tumor therapy, the first section of this review demonstrates the association between plasma membrane physicochemical properties and tumor signaling, metastasis, and drug resistance. The second section highlights existing nanotherapeutic strategies for membrane disruption, including lipid peroxide accumulation, cholesterol regulation, membrane structure disruption, lipid raft immobilization, and energy-mediated plasma membrane perturbation. Finally, the third section evaluates the prospects and challenges of plasma membrane lipid perturbing therapy as a therapeutic strategy for cancers. The reviewed membrane lipid perturbing tumor therapy strategies are expected to bring about necessary changes in tumor therapy in the coming decades.
Keywords: plasma membrane, nanotechnology, tumor, lipid, perturbing
Citation styles
APA
Fei, W., Yan, J., Wu, X., Yang, S., Zhang, X., Wang, R., Chen, Y., Xu, J., Zheng, C. (2023). Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics. Theranostics, 13(8), 2471-2491. https://doi.org/10.7150/thno.82189.
ACS
Fei, W.; Yan, J.; Wu, X.; Yang, S.; Zhang, X.; Wang, R.; Chen, Y.; Xu, J.; Zheng, C. Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics. Theranostics 2023, 13 (8), 2471-2491. DOI: 10.7150/thno.82189.
NLM
Fei W, Yan J, Wu X, Yang S, Zhang X, Wang R, Chen Y, Xu J, Zheng C. Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics. Theranostics 2023; 13(8):2471-2491. doi:10.7150/thno.82189. https://www.thno.org/v13p2471.htm
CSE
Fei W, Yan J, Wu X, Yang S, Zhang X, Wang R, Chen Y, Xu J, Zheng C. 2023. Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics. Theranostics. 13(8):2471-2491.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.